10x Genomics, Inc. (NASDAQ: TXG) is a Healthcare company (Biotechnology) with a market capitalization of $6.8B. The Maz Rating grades it against the other companies in its sector.
10x Genomics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $56.13, 10x Genomics, Inc. trades at 10.8x sales and 8.6x book value, with an EV/EBITDA of 139.5. Over the last twelve months it generated about $631M of revenue and a net loss of $64M. It runs a gross margin of 71.9%, an operating margin of -11.7% and a net margin of -10.8%. It shows return on equity of -8.2%, return on invested capital of -7.7% and a free cash flow yield of 1.4%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 5.12. Over the past 52 weeks the share price ranged from $15.18 to $102.81, with a beta of 2.03.
10x Genomics, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 10 Buy, 11 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, 10x Genomics, Inc. (TXG) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.25% / 30% · Interest income / Revenue 3.33% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.25% / 33% · Receivables / Mkt Cap (36m) 0.64% / 49% · Interest income / Revenue 3.33% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.25% / 33.33% · Receivables / Mkt Cap (24m) 0.64% / 33.33% · Interest income / Revenue 3.33% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 2.32% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 52.8% / 33.33% · Receivables / Avg Assets (4Q) 5.98% / 33.33% · Interest income / Revenue 3.33% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 54.1% / 33.33% · (Cash+Recv) / Total Assets 59.7% / 33.33% · Interest income / Revenue 3.33% / 5% | Fail |
It depends on the standard you follow. As of September 2026, 10x Genomics, Inc. (TXG) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. 10x Genomics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.33% of each dividend: 10x Genomics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.